| CEO Name | Thomas J. Appio |
| Nationality | United States |
| Net Worth Estimation | $25 million |
Thomas J. Appio's estimated net worth of around $25 million is primarily attributed to his executive compensation, equity awards, and stock ownership accumulated through his roles at Bausch Health Companies Inc. and previous senior leadership positions in the pharmaceutical industry. His wealth reflects his salary, bonuses, vested shares, and long-term incentive plans.
Thomas J. Appio, CEO of Bausch Health Companies Inc., has an estimated net worth of $25,000,000, which represents 21.43% of the maximum and 250% of the minimum CEO net worth in the healthcare industry range provided. His net worth positions him slightly above the industry midpoint.
Business Category: Healthcare
Minimum Net Worth (estimation): 10000000 USD
Maximum Net Worth (estimation): 90000000 USD
Thomas J. Appio Performance in Bausch Health Companies Inc.
Thomas J. Appio, CEO of Bausch Health Companies Inc., demonstrates strategic leadership by prioritizing innovation and operational efficiency to drive company growth. His decisive management style emphasizes data-driven decision-making and portfolio optimization, significantly enhancing the firm's competitive positioning. Under Appio's leadership, Bausch Health has improved financial performance and expanded its market presence, solidifying its stance in the pharmaceutical and medical products industry.
Latest News
Bausch Health Companies Inc. Reports Steady Growth and Strategic Developments in 2025
Bausch Health reported a 5% revenue increase year-over-year to $2.53 billion in Q2 2025, highlighting steady growth and a $7.9 billion debt refinancing; Chairman John Paulson raised his stake to 19.13%, signaling strong confidence amid board restructuring. CEO Joseph C. Papa, leading since 2016, has driven transformation including a major company rebranding from Valeant to Bausch Health in 2018 and ongoing innovation in diverse healthcare segments.
Source: http://www.investing.com/news/transcripts/earnings-call-transcript-bausch-health-q2-2025-sees-steady-growth-strategic-moves-93CH-4287491